Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188694 · ClinicalTrials.gov registry record · Phase 2
Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01188694 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 42 participants.
The verdict
NCT01188694, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Posttraumatic stress disorder (PTSD) is a condition that involves intense memories of a traumatic event and intense, persistent feelings of anxiety. There are several effective therapies for PTSD, but they are often time consuming. The investigators want to see if the investigators can shorten treatment time while keeping therapy effective by adding a medication called methylene blue, USP, taken orally as a pill, to the therapy. The specific aims are: 1) To see whether medication plus psychotherapy improves PTSD symptoms more than placebo plus psychotherapy or a waitlist; 2) To examine the long-term outcome of those receiving medication plus psychotherapy 1 and 3 months after treatment has ended; 3) To examine whether medication plus psychotherapy helps with depression, trauma-related cognitions, and functioning.
Interventions
- DRUG Psychotherapy plus Methylene Blue, USP
- BEHAVIORAL Psychotherapy plus Placebo
- BEHAVIORAL Delayed Psychotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01188694
The ClinicalTrials.gov registry entry for NCT01188694 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Psychotherapy plus Methylene Blue, USP is the first listed.
NCT01188694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01188694 about?
NCT01188694 is a clinical study titled "Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)". Posttraumatic stress disorder (PTSD) is a condition that involves intense memories of a traumatic event and intense, persistent feelings of anxiety. There are several effective therapies for PTSD, but they are often time consuming. The investigators want to see if the investigators can shorten treat...
What is the current status of trial NCT01188694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2009-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01188694?
The interventions under investigation include: Psychotherapy plus Methylene Blue, USP (DRUG), Psychotherapy plus Placebo (BEHAVIORAL), Delayed Psychotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01188694?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.